Monte Rosa Therapeutics (GLUE) Retained Earnings (2020 - 2026)

Monte Rosa Therapeutics' Retained Earnings history runs 7 years deep, the most recent figure standing at -$521.7 million for Q1 2026.

• On a quarterly basis, Retained Earnings fell 33.19% year-over-year to -$521.7 million in Q1 2026; TTM through Mar 2026 was -$521.7 million, a 33.19% decrease from a year earlier, with the FY2025 full-year figure at -$3.8 million, down 14.03% from the prior year.
• Retained Earnings retreated to -$521.7 million in Q1 2026 per GLUE's latest filing, from -$3.8 million in the prior quarter.
• Across five years, Retained Earnings topped out at -$1.5 million in Q3 2023 and bottomed at -$521.7 million in Q1 2026.
• The 5-year median for Retained Earnings is -$3.4 million (2025), against an average of -$138.8 million.
• Across the five-year window, Retained Earnings jumped 99.27% in 2023 and sank 14445.12% in 2025, its largest moves.
• Year by year, Retained Earnings stood at -$230.5 million in 2022, then surged by 98.82% to -$2.7 million in 2023, then decreased by 23.2% to -$3.4 million in 2024, then slipped by 14.03% to -$3.8 million in 2025, then plunged by 13532.53% to -$521.7 million in 2026.
• Per Business Quant, the three latest GLUE Retained Earnings figures stand at -$521.7 million (Q1 2026), -$3.8 million (Q4 2025), and -$3.2 million (Q3 2025).